MK-677 vs GHRP-6
Both MK-677 and GHRP-6 are used for growth-hormone. Here's how their evidence, dosing, and regulatory status actually compare.
MK-677
Evidence B+Ibutamoren (MK-677)
An orally active ghrelin-receptor agonist that drives 24-hour increases in GH and IGF-1. Technically a non-peptide small molecule but always grouped with GH peptides.
View full MK-677 profile →GHRP-6
Evidence BGrowth Hormone Releasing Peptide 6
An older GHS that produces strong appetite stimulation in addition to GH release. Largely supplanted by Ipamorelin and GHRP-2 for clinical use but still common in research stacks.
View full GHRP-6 profile →Side-by-Side
| Attribute | MK-677 | GHRP-6 |
|---|---|---|
| Evidence Grade | B+ | B |
| FDA Status | Not FDA-approved — investigational (orally active GH secretagogue) | Not FDA-approved — research compound |
| Typical Dose | 10–25 mg orally, once daily | 100–300 mcg, 1–3 times daily (subcutaneous) |
| Clinics Indexed | 165 | 64 |
| Categories | growth-hormone, anti-aging | growth-hormone, appetite |
Key reported benefits — MK-677
- ✓Sustained GH/IGF-1 elevation
- ✓Sleep depth
- ✓Lean mass
- ✓Bone density
Key reported benefits — GHRP-6
- ✓GH release
- ✓Appetite stimulation
- ✓Cytoprotection
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.